Cover Image

Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review

Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease caused by <i>Mycobacterium tuberculosis</i> which is resistant to at least isoniazid and rifampicin. This disease is a worldwide threat and complicates the control of tuberculosis (TB). Long treatment duration, a combinat...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rhea Veda Nugraha (Author), Vycke Yunivita (Author), Prayudi Santoso (Author), Rob E. Aarnoutse (Author), Rovina Ruslami (Author)
Format:	Book
Published:	MDPI AG, 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clofazimine for the treatment of tuberculosis
by: Jacob A. M. Stadler, et al.
Published: (2023)

A Mixed-Method Study of Medication-Related Burden Among Multi-Drug Resistant Tuberculosis Patients in West Java, Indonesia
by: Ausi Y, et al.
Published: (2024)

Polymorphisms of SLCO1B1 Gene in Sundanese Ethnic Population of Tuberculosis Patients in Indonesia
by: Prayudi Santoso, et al.
Published: (2022)

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters
by: Nurul Annisa, et al.
Published: (2022)

Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems
by: Daniélle van Staden, et al.
Published: (2022)

Mannose receptor targeted bioadhesive chitosan nanoparticles of clofazimine for effective therapy of tuberculosis
by: Datta Maroti Pawde, et al.
Published: (2020)

Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment
by: Druva Sarika Rongala, et al.
Published: (2024)

Representations on adherence to the treatment of Multidrug-Resistant Tuberculosis
by: Kuitéria Ribeiro Ferreira, et al.
Published: (2018)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
by: Szumowski JD, et al.
Published: (2015)

Clofazimine: A Promising Inhibitor of Rabies Virus
by: Jiajing Wu, et al.
Published: (2021)

An updated literature review concerning the treatment cost of multidrug-resistant tuberculosis
by: Quang Vinh Tran, et al.
Published: (2018)

Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
by: Fanta Desissa, et al.
Published: (2018)

Multidrug-resistant tuberculosis today
by: A Matteelli, et al.

Multidrug-resistant tuberculosis today
by: A Matteelli, et al.
Published: (2012)

A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
by: Melissa S Love, et al.
Published: (2017)

Disadvantage and the experience of treatment for multidrug-resistant tuberculosis (MDR-TB)
by: Holly A. Taylor, et al.
Published: (2022)

Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru
by: Dylan B. Tierney MD MPH, et al.
Published: (2016)

Nomogram to predict multidrug-resistant tuberculosis
by: Saibin Wang, et al.
Published: (2020)

Risk Factors for Multidrug-resistant Tuberculosis
by: Cleopas Martin Rumende
Published: (2018)

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
by: Ronald Anderson, et al.
Published: (2018)

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis
by: Taher Azimi, et al.
Published: (2022)

Anti-Tuberculosis Activity of Three Carbapenems, Clofazimine and Nitazoxanide Using a Novel Ex Vivo Phenotypic Drug Susceptibility Model of Human Tuberculosis
by: Ximena Gonzalo, et al.
Published: (2022)

Individualised treatment for multidrug‐resistant tuberculosis in New South Wales, Australia
by: Vicky Chang, et al.
Published: (2021)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
by: Haoyue Zhang, et al.
Published: (2023)

TUBERCULOSIS WITH MULTIDRUG-RESISTANT AND EXTENSIVELY DRUG-RESISTANT OF MICOBACTERIUM TUBERCULOSIS IN THE RUSSIAN FEDERATION
by: A.E. ERGESHOV, et al.
Published: (2018)

Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis
by: Kai Blöndal

Young patient with complicated multidrug-resistant tuberculosis
by: Cristóbal Gallego Muñoz, et al.
Published: (2016)

Adolescence, multidrug resistant tuberculosis, bedaquine and videotapes
by: Anna Gamell, et al.
Published: (2023)

Obstacles in combating multidrug resistant tuberculosis in pediatric patients: a scope review
by: Letícia Baltar Sobreira, et al.
Published: (2024)

Improved in vitro potency of Clofazimine derivatives against Neisseria species
by: Masahide Yano, et al.
Published: (2024)

Factors Influencing Private Practitioners to Report Tuberculosis Cases
by: Anneke Rosma, et al.
Published: (2016)

Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility
by: Kaspars Lunte, et al.

Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes.
by: Keri Geiger, et al.
Published: (2024)

Multidrug-Resistant Tuberculosis in Portugal: Patients' Perception of the Challenges Faced during Treatment
by: Marcela Bhering, et al.
Published: (2020)

Patient- and provider-related factors in the success of multidrug-resistant tuberculosis treatment in Colombia
by: Gloria Mercedes Puerto Castro, et al.
Published: (2021)

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
by: Paul J Converse, et al.
Published: (2015)

Synthesis and Characterization of a Biomimetic Formulation of Clofazimine Hydrochloride Microcrystals for Parenteral Administration
by: Mikhail D. Murashov, et al.
Published: (2018)

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine
by: Silvia Shinpei Chiang, et al.
Published: (2019)

Principles for designing future regimens for multidrug-resistant tuberculosis
by: Grania Brigden, et al.
Published: (2014)

Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis
by: Luiz Henrique Arroyo, et al.